Peplin, Inc.
Peplin Results for the Financial Year Ended 30 June 2009
Published in Medical Letter on the CDC and FDA, September 20th, 2009
Peplin, Inc. (ASX:PLI) announced financial results for the year ended 30 June 2009, reporting a US$17.7 million cash balance. Peplin will use these funds to complete Phase 3 clinical trials for its lead product, PEP005 (ingenol mebutate) Gel for actinic (solar) keratosis (AK). The company is confident it will have access to sufficient working capital to fund operations through its planned New Drug Application (NDA) filing with the Food and Drug Administration (FDA) in mid-2010.
Chairman and CEO Tom Wiggans described the year as one of tremendous progress for Peplin.
"Peplin's achievements this year of advancing PEP005 Gel through the completion of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Bioluminescence
New bioluminescence study findings recently were reported by Y.M. Zhang and co-researchers - Campaign for Safe Cosmetics
FDA Study: Lead Levels in Lipstick Much Higher Than Previously Reported - Enzyme Research
Reports on enzyme research findings from R. Gozalbes and co-researchers provide new insights - Flu Vaccines
NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine Candidate - iTech Medical
Impact Medical Solutions, Inc. dba iTech Medical Engages D&D Securities Company - Life Sciences
Researchers at Brigham and Women's Hospital publish new data on life sciences - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
